GlassScriptPhysician profile
Amy J Nation
NPI 1124001326
$1,191.89
in general payments reported to CMS, 2019-2025
31 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $261 · 2021: $111 · 2022: $145 · 2023: $96.48 · 2024: $323 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.05 | 2022-2024 | |
| Pfizer INC. | $97.56 | 2020-2025 | |
| Lilly USA, LLC | $84.68 | 2020-2025 | Jardiance, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $78.95 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $65.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $61.44 | 2020-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $47.73 | 2021-2025 | Spravato |
| Allergan, INC. | $40.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.71 | 2022-2025 | |
| Renalytix Ai, INC. | $38.28 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $38.03 | 2021-2023 | |
| Exact Sciences Corporation | $37.25 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $34.74 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.90 | 2019-2020 | |
| Amgen INC. | $31.70 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $30.46 | 2024 | Qutenza |
| Photonicare INC | $28.79 | 2024 | Otosight Middle Ear Scope |
| Sanofi-Aventis U.S. LLC | $27.40 | 2024 | |
| Ironshore Pharmaceuticals INC. | $23.92 | 2020 | |
| Amneal Pharmaceuticals LLC | $21.90 | 2020 | |
| Abbott Laboratories | $21.26 | 2024 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $20.19 | 2020 | |
| Genentech USA, INC. | $19.17 | 2019 | |
| Esperion Therapeutics, INC. | $19.00 | 2024 | Nexletol |
| Hologic Sales and Service, LLC | $18.74 | 2019 | |
| Tolmar, INC. | $18.26 | 2023 | |
| Vistapharm, INC. | $14.92 | 2021 | |
| Sanofi Pasteur INC. | $14.83 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.73 | 2024 | Quviviq |
| Daiichi Sankyo INC. | $12.97 | 2021 | |
| Ethicon US, LLC | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Nation listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.